Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients (Q24246340)

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Median effect analysis of efficacy versus adverse effects of immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Rapamycin: clinical results and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Phase III trial of Rapamune versus placebo in primary renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Kidney transplantation without calcineurin inhibitors using sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Problems and Limitations in Conducting Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Surrogate markers for long-term renal allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Poor predictive value of serum creatinine for renal allograft loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Long-term deterioration of kidney allograft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Early clinical experience with a novel rapamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Predicting long-term kidney graft survival: can new trials be performed?1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Sirolimus and everolimus for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

Improved graft survival after renal transplantation in the United States, 1988 to 1996

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021

Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004290.PUB2

7 January 2021